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1. Summary
Missense mutations of the phosphatase and tensin homolog (PTEN)-induced
kinase 1 (PINK1) gene cause autosomal-recessive Parkinson’s disease. To date,
little is known about the intrinsic catalytic properties of PINK1 since the
human enzyme displays such low kinase activity in vitro. We have discovered
that, in contrast to mammalian PINK1, insect orthologues of PINK1 we have
investigated—namely Drosophila melanogaster (dPINK1), Tribolium castaneum
(TcPINK1) and Pediculus humanus corporis (PhcPINK1)—are active as judged
by their ability to phosphorylate the generic substrate myelin basic protein. We
have exploited the most active orthologue, TcPINK1, to assess its substrate speci-
ficity and elaborated a peptide substrate (PINKtide, KKWIpYRRSPRRR) that can
be employed to quantify PINK1 kinase activity. Analysis of PINKtide variants
reveal that PINK1 phosphorylates serine or threonine, but not tyrosine, and we
show that PINK1 exhibits a preference for a proline at the þ1 position relative
to the phosphorylation site. We have also, for the first time, been able to investi-
gate the effect of Parkinson’s disease-associated PINK1 missense mutations, and
found that nearly all those located within the kinase domain, as well as the
C-terminal non-catalytic region, markedly suppress kinase activity. This empha-
sizes the crucial importance of PINK1 kinase activity in preventing the
development of Parkinson’s disease. Our findings will aid future studies aimed
at understanding how the activity of PINK1 is regulated and the identification
of physiological substrates.
& 2011 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.2. Introduction
Mutations in the protein kinase PINK1 (PTEN-induced
kinase 1) gene cause hereditary Parkinson’s disease [1].
Patients harbouring PINK1 mutations typically present with
early-onset Parkinson’s disease, with a mean age of onset
in their 30s [2]. Currently, Parkinson’s disease remains
incurable and treatment is aimed at relieving symptoms.
PINK1 encodes a protein of 581 residues, and is unique
among all kinases as it is targeted to the mitochondria by
an N-terminal mitochondrial targeting sequence (residues
1–34) and a transmembrane a-helix (residues 94–110) [3].
The catalytic domain of PINK1 (residues 150–513) is not
closely related to other protein kinases as it features three
unique insertions between the beta strands that make up
the typical fold of the N-lobe of protein kinases (figure 1;
electronic supplementary material, figure S1). In addition,
PINK1 contains a C-terminal non-catalytic region of
unknown function (residues 514–581).
ThefunctionofPINK1remainspoorlyunderstood,although,
in mammalian cells, several studies suggest that PINK1 controls
another Parkinson’s disease-associated enzyme, namely the
parkin E3 ligase, by recruiting it to the mitochondrial membrane
through an as-yet-undefined mechanism [4–7]. While PINK1
knock-out mice display no significant phenotype [8], Drosophila
PINK1 null flies exhibit a striking phenotype sharing many
overlapping behavioural and cellular features with human
Parkinson’s disease, including motor deficits, neuronal loss and
mitochondrial abnormalities [9,10]. This phenotype is rescued
by over-expression of wild-type (but not kinase-inactive)
DrosophilaPINK1[11]andcanalsoberescuedbyover-expression
of human wild-type PINK1 [12,13].
A major obstacle in studying PINK1 has been the diffi-
culty in assessing its intrinsic catalytic properties since
recombinant human PINK1 displays no significant activity.
In this study, we have discovered that, in contrast to
human PINK1, the three insect orthologues of PINK1 that
we have examined display significant protein kinase activity
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Figure 1. Identification of orthologues of PINK1. (a) Multiple sequence alignment of PINK1 from human, T. castaneum, P. humanus corporis and D. melanogaster.
The start and the end of the kinase domain are indicated by red arrows, and the three insertions within the kinase domain discussed in the text are marked with
blue bars. (b) Schematic of domain structure of PINK1 orthologues in human, T. castaneum, P. humanus corporis and D. melanogaster, with numbering corresponding
to the human sequence. MTS, mitochondrial targeting sequence; TM, transmembrane helix; INS, insertion; CTD, C-terminal domain.
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2when expressed in Escherichia coli. This has enabled us for the
first time to investigate the substrate specificity of PINK1 and
demonstrate that most Parkinson’s disease-associated mis-
sense mutations ablate or markedly inhibit PINK1 kinase
activity. These findings provide the first insights into some
of the intrinsic properties of PINK1 and emphasize the crucial
requirement of intact PINK1 kinase activity in preventing the
development of Parkinson’s disease. These findings will
be helpful for future investigation of PINK1 and its role in
Parkinson’s disease.
3. Results
3.1. Identification of insect PINK1 orthologues that are
active protein kinases
The strongest evidence suggesting that PINK1 is an active
kinase is the striking observation that the Drosophila PINK1
null phenotype can be rescued by wild-type but not by
kinase-inactive PINK1 [11]. This inspired us to investigate
w h e t h e ri n s e c to r t h o l o g u e so fP INK1 from different species
were active protein kinases. We studied Drosophila PINK1
(dPINK1) as well as two other insect species: Tribolium casta-
neum (TcPINK1) and Pediculus humanus corporis (PhcPINK1).
TcPINK1 and PhcPINK1 lack the first insertion in the kinase
domain, whereas dPINK1 possesses an insertion, which
is considerably longer than that seen in human PINK1 (figure 1;
electronic supplementary material, figures S1 and S2). We
expressed the full-length forms of TcPINK1, PhcPINK1 and
dPINK1 in E. coli, and tested their ability to phosphory-
late myelin basic protein (MBP), a generic kinase substrate
(figure 2a). Strikingly, the three insect PINK1 orthologues
were active as judged by their ability to phosphorylate MBP
(figure 2a). Consistent with the activity being mediated by
PINK1 itself, a kinase-inactivating mutation targeting the mag-
nesium-binding Asp residue within the catalytic domain of
each orthologue abolished MBP phosphorylation. We observed
that TcPINK1 and PhcPINK1 were more active than dPINK1,
with TcPINK1 displaying the highest specific activity (figure
2a). In parallel experiments, we also tested whether the longest
fragment of human PINK1 (125–581) that we were able to
express in either E. coli or insect Sf9 cells (figure 2a)w a s
active. Consistent with previous work, we found that human
PINK1 displayed no significant kinase activity (figure 2a).
We also observed that two reported PINK1 interactors,
TRAP1 [14] and Omi [15], were not phosphorylated by insect
or human PINK1 (electronic supplementary material, figure S3).
We next expressed full-length as well as truncated forms
of TcPINK1 lacking the N-terminal and/or C-terminal
domains in E. coli (figure 2b). Full-length or fragments lack-
ing the non-catalytic N-terminal domain of TcPINK1
robustly phosphorylated MBP; however, deletion of the C-
terminal non-catalytic domain of TcPINK1 abolished MBP
phosphorylation, suggesting that this region is required for
activity (figure 2b). Furthermore, TcPINK1 phosphorylated
MBP to a greater extent than histone H1 and casein (elec-
tronic supplementary material, figure S4). Full-length
PhcPINK1 also phosphorylated MBP and histone H1 simi-
larly to TcPINK1 (electronic supplementary material,
figure S4). Human PINK1, expressed in either E. coli or
Sf9 cells, failed to phosphorylate any of these substrates
(electronic supplementary material, figure S5).
We also noted that both wild-type (but not kinase-inactive)
TcPINK1 and PhcPINK1 underwent autophosphorylation
when incubated with Mg-ATP (figure 2b; see also electronic
supplementary material, figures S4 and S5). We mapped the
sites of autophosphorylation in wild-type TcPINK1 after incu-
bation with Mg-ATP by LC-MS-MS on a 4000 QTRAP mass
spectrometer using precursor ion scanning to detect the loss
of an HPO3-i o n( 279) from a peptide. This led to the detection
of a peptide in which one of two nearby serine residues,
Ser205 and Ser207, was phosphorylated, although it was not
possible to unambiguously decipher which of these residues
was autophosphorylated (electronic supplementary material,
figure S6a). These Ser residues are located within the N-lobe
of the kinase domain of PINK1 (figure 1a; electronic sup-
plementary material, figure S1). Mutation of Ser205 to Ala
led to a significant reduction in PINK1 kinase activity, whereas
mutation of Ser207 only modestly reduced kinase activity
(electronic supplementary material, figure S6b). The double
Ser205Ala þ Ser207Ala mutant possessed lowered activity
similar to the single Ser205Ala mutant (electronic supplemen-
tary material, figure S6b). The Ser205 and Ser207 residues are
conserved in mammalian PINK1 (Ser228 and Ser230 in
human PINK1, respectively), and further work would be
required to assess the importance of autophosphorylation of
these residues.
3.2. TcPINK1 and PhcPINK1 rescue the locomotor
phenotype in PINK1-deficient Drosophila
To verify that TcPINK1 and PhcPINK1 were true orthologues
of PINK1, we tested whether TcPINK1 or PhcPINK1 could
rescue locomotor defects in Drosophila PINK1 null flies. Mul-
tiple transgenic lines bearing TcPINK1 or PhcPINK1 under
the control of the inducible GAL4/UAS system were com-
bined into a PINK1 mutant background, and found to
rescue the flight and climbing defects as well as the
appearance of thoracic indentations that are attributed to
loss of PINK1 (figure 2c; electronic supplementary material,
figure S7).
3.3. Analysis of PINK1 substrate specificity
and elaboration of an optimal peptide
substrate, PINKtide
To investigate the substrate specificity of TcPINK1, we used
a positional scanning library approach [16,17], in which
the ability of TcPINK1 to phosphorylate 198 biotinylated pep-
tide libraries simultaneously was assessed. Each library
contains a 1:1 serine and threonine at the central position,
and one additional position fixed to one of the 20 amino
acids and phospho-threonine and phospho-tyrosine. Phos-
pho-tyrosine and phospho-threonine were included to allow
for identification of kinases requiring priming phosphoryl-
ation events. All other positions contain an equimolar
degenerate mixture of natural amino acids (except serine,
threonine and cysteine). Recombinant full-length wild-type
or kinase-inactive TcPINK1 were used to phosphorylate
all peptide libraries in solution using [g-
32P] ATP, and
biotinylated peptides were captured on a streptavidin-
coated membrane. The relative preference for each amino
acid at each position was determined by quantifying
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432P incorporation by phospho-imaging. This revealed a pre-
ference for a proline at the þ1 position and a general
preference at several residues for basic residues such as argi-
nine. There were also moderate preferences for a phospho-
tyrosine at the 23 position and a tryptophan at the 25 pos-
ition (figure 3a). In a parallel experiment, there was negligible
phosphorylation of peptides for the experiments undertaken
with the kinase-inactive TcPINK1 (figure 3a).
The data from the positional scanning peptide library
suggested that the optimal TcPINK1 phosphorylation motif
between the 25 and the þ4 position was WIpYRRSPRRR,
in which the underlined Ser comprises the site of
phosphorylation. We observed that wild-type but not
catalytically inactive TcPINK1 significantly phosphorylated
this peptide (in which two Lys residues were added to the
N-terminus to improve solubility), with a Km of approxi-
mately 500 mM and a Vmax of approximately 10 U mg
21 for
TcPINK1 (figure 3b and electronic supplementary material,
figure S8). This peptide (KKWIpYRRSPRRR) was termed
PINKtide. Changing the phosphorylated Ser residue to Thr
did not affect phosphorylation (figure 3b), suggesting that
PINK1 could phosphorylate substrates at either Ser or Thr
residues. Mutation of the phosphorylation site to Tyr abol-
ished phosphorylation (figure 3b), confirming that PINK1 is
a Ser/Thr-specific kinase. TcPINK1 also failed to signifi-
cantly phosphorylate a panel of 11 previously described
peptide substrates used to assess catalytic activity of diverse
kinases, including CDKtide, which contains a þ1 proline
required for phosphorylation by the CDK kinases (electronic
supplementary material, figure S9).
Mutation of the Pro residue at the þ1 position of
PINKtide to a Phe, Leu, Ala, Lys or Glu virtually aboli-
shed phosphorylation by TcPINK1, indicating that PINK1
may possess a marked preference for phosphorylation of
Ser/Thr residues that have a þ1 Pro residue (figure 3c).
We next investigated the effect of mutating the 23 and 25
residues that are the critical determinants of substrate
specificity for many kinases [18]. Mutation of the 25T r p
residue to five other residues, although lowering the Km up
to threefold, concomitantly decreased Vmax up to fourfold
(with the exception of alanine), thus not altering steady-
state kinetics significantly (figure 3b). Mutation of the 23
phospho-tyrosine residue to tyrosine markedly reduced the
Km (16-fold), but also lowered the Vmax threefold (figure
3b). We also mutated the 23 residues to seven other residues
but found that although many of these lowered the Km, they
alsoresultedinsignificantdecreasesinVmax(figure3b).Outof
the approximately 20 peptidestested, none displayed a higher
Vmax value than PINKtide (figure 3b).
3.4. Impact of Parkinson’s disease mutations on
TcPINK1 catalytic activity
We determined the effects of Parkinson’s disease-associated
mutations on PINK1 catalytic activity by selecting 14
homozygous or compound heterozygous missense muta-
tions that lead to early-onset Parkinson’s disease in which
the disease-associated amino acid residue is conserved in
TcPINK1 (figure 4a; electronic supplementary material,
table S1). All bar one of the selected mutations are located
within the kinase domain (figure 4a, inset). We observed
that all mutants investigated were expressed in E. coli at
comparable levels and purity to wild-type TcPINK1
(figure 4a). Measuring specific activity against both PINK-
tide (figure 4a) and MBP (electronic supplementary
material, figure S10) revealed that 12 mutations lying
within the kinase domain (A217D, E240K, H271Q, L347P,
L369P, G386A, C388R, G409V, P416R, E417G, G440E and
L489P) virtually abolished or ablated kinase activity. One
mutation, G309D, which lies within the third kinase
domain insertion, reduced kinase activity by 90 per cent.
The only other mutation studied that was not situated
within the kinase domain (C125G) only moderately reduced
kinase activity.
Nonsense mutations of PINK1 that lead to truncation of
PINK1 and the loss of the C-terminal non-catalytic domain,
as well as a small portion of the kinase domain, have also
been reported (figure 4b, inset). Two of these mutations,
W437X (originally found in the Marsala kindred) [1] and
Q456X [19], are inherited in a homozygous recessive
manner, while a third, R492X, has been found as a compound
heterozygous mutation [19] (electronic supplementary
material, table S1). We introduced these mutations into
TcPINK1 and tested their activity against either PINKtide
(figure 4b) or MBP (electronic supplementary material,
figure S11), and found that all of the truncating mutations
tested abolished kinase activity.
4. Discussion
In contrast to human PINK1, we report that insect orthologues
of PINK1, including Drosophila melanogaster, T. castaneum
(TcPINK1) and P. humanus corporis (PhcPINK1), exhibit
Figure 2. (Opposite.) Characterization of active insect orthologues of PINK1. (a) Assessment of activity of wild-type N-terminally truncated human PINK1 (125–581)
expressed in E. coli and Sf9 cells, full-length D. melanogaster PINK1 (dPINK1, 1–721), T. castaneum PINK1 (TcPINK1, 1–570) and P. humanus corporis PINK1
(PhcPINK1, 1–575), and corresponding kinase-inactive mutants (HsPINK1-D384A, dPINK1-D501A, TcPINK1-D359A, PhcPINK1-D357A) against myelin basic protein
(MBP). The indicated enzymes (1 mg) were incubated in the presence of 5 mg MBP and [g-
32P] ATP for 30 min. Reactions were terminated by spotting on P81
paper, washing in phosphoric acid and quantifying phosphorylation of myelin basic protein. The results are presented as +s.d. for a representative experiment
undertaken in duplicate (upper panel). In the lower panel, representative Coomassie-stained gels showing the relative amounts of PINK1 enzyme used for each assay
are shown. Fine dividing lines indicate that reactions were resolved on separate gels and grouped in the final figure. (b) Assessment of kinase activity of wild-type or
kinase inactive (D359A) full-length (1–570), N-terminal truncation (128–570 and 155–570) and N- and C-terminal truncation mutants (155–486) of TcPINK1. The
indicated forms of TcPINK1 (1 mg) were incubated in the presence (þ) or absence (2) of myelin basic protein (2 mM) and [g-
32P] ATP for 30 min. Reactions were
terminated by the addition of SDS sample buffer and separated by SDS-PAGE. Gels were analysed by Coomassie staining (upper panel) and incorporation of[ g-
32P]
ATP was detected by autoradiography (lower panel). Fine dividing lines indicate that reactions were resolved on separate gels and grouped in the final figure.
(c) Analysis of T. castaneum and P. humanus corporis PINK1 function in vivo. TcPINK1 or PhcPINK1 was ectopically expressed in Drosophila lacking endogenous PINK1.
Flight ability, climbing ability and presence of thoracic indentations were quantified. Genotypes are as follows. Control: PINK1
B9/þ, mutant: PINK1
B9/Y; da-GAL4/þ,
mutant rescue: PINK1
B9/Y; da-GAL4/þ, UAS-Tb.PINK1
2a/þ or PINK1
B9/Y; da-GAL4/þ, UAS-Phc.PINK1
1/þ. Data are presented as mean+s.e.m.
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5significant catalytic kinase activity in vitro (figure 1). Using the
most active orthologue, TcPINK1, we have been able to
describe the first investigation of the substrate specificity of
PINK1 and we have used this information to elaborate a
novel peptide substrate, KKWIpYRRSPRRR (figure 3), which
we have designated PINKtide. We have employed PINKtide
to probe the effect that Parkinson’s disease-associated
mutations exert on PINK1 kinase activity (figure 4; electronic
supplementary material, figure S10). A key question concerns
why PINK1 from insect species is active, whereas human
PINK1 is inactive when expressed in a similar manner
(figure 2a; electronic supplementary material, figure S5). It is
possible that mammalian PINK1 is not active as it is regulated
in a more complex manner, and that additional interactors
and/or covalent modifications not present in E. coli or insect
hosts (used to express human PINK1 in our studies) are
required to activate human PINK1.
Our results suggest that missense PINK1 mutations situ-
ated within the kinase domain exert their Parkinson’s
disease-causing effects by markedly suppressing kinase
activity (figure 4a). This emphasizes the importance of iden-
tifying the key physiological substrates of PINK1 in order to
understand how the loss of kinase activity leads to neuro-
degeneration in Parkinson’s disease. To date, no robust
substrates of PINK1 have been discovered, partly owing to
the unavailability of active recombinant PINK1. We have
also evaluated some of the previously described PINK1 inter-
actors (TRAP1 [14] and Omi [15]), and found that neither of
them were significantly phosphorylated in vitro by insect
PINK1 (electronic supplementary material, figure S3), there-
fore suggesting that these are not directly phosphorylated by
PINK1. It would also be interesting to establish whether
sites of PINK1 phosphorylation identified in substrates in
the future lie within Ser/Thr-Pro motifs that might be pre-
dicted from our initial analysis of PINK1 substrate
specificity. We have also attempted to map the sites on
myelin basic protein that were phosphorylated by TcPINK1
and found numerous sites were phosphorylated at a very
low stoichiometry (data not shown). This confirms that
myelin basic protein is not an optimal substrate for PINK1.
Wewouldpredict that PINK1 wouldphosphorylateagenuine
substrate at a distinct site(s) at significant stoichiometry.
The C-terminus of PINK1 has no homology to any known
protein. We have found that removal of the C-terminus of
TcPINK1 (486–570), equivalent to residues 513–581 in
human PINK1, abolishes TcPINK1 kinase activity, and also
that the three C-terminal truncating disease mutants W437X,
Q456X and R492X ablate kinase activity (figure 4b;
electronic supplementary material, figure S10). Our data are
also consistent with recent Drosophila data showing that
human wild-type PINK1 but not C-terminal-truncated
human PINK1 (residues 1–509) could rescue the Drosophila
PINK1 null phenotype [13]. It would be interesting to under-
take further analysis to establish how the C-terminal domain
might regulate kinase activity.
In the future, it will also be vital to solve the atomic
structure of PINK1 to fully understand how the enzyme is
regulated and to understand the molecular mechanism by
which mutations inhibit kinase activity. The observation
that the C125G mutation lying outside the kinase domain
only modestly impaired kinase activity suggests that this
mutation affects PINK1 function by a distinct mechanism.
As the C125G mutation is close to the transmembrane
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Figure 3. Elaboration of the PINKtide substrate for TcPINK1. (a) Full-length
(1–570) (i) wild-type and (ii) kinase-inactive (D359A). TcPINK1 was used to
screen a positional scanning peptide library of 198 biotinylated peptide
libraries. Reaction products were bound to a streptavidin-coated membrane,
washed and visualized by phospho-imaging. The small red dots indicate the
residues selected for the PINKtide peptide sequence. (b) Kinetics of
phosphorylation of PINKtide and indicated variants by full-length TcPINK1
(1–570).ResiduesthatwerechangedrelativetoPINKtideareindicatedinbold.
Km and Vmax values were derived by nonlinear regression analysis as described
in §5. n.d. denotes that a particular peptide was phosphorylated poorly and
kinetic values were not determinable. Similar results were obtained in at least
two experiments. (c) Kinetics of phosphorylation of mutants of PINKtide at the
þ1 position by full-length TcPINK1 (1–570) in a representative experiment to
illustrate the marked preference for a þ1 Pro residue.
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Figure 4. Effect of Parkinson’s disease mutation on PINK1 kinase activity. (a) Inset: Schematic of the location of missense PINK1 mutations where the wild-type
residue is conserved in both human PINK1 and TcPINK1. Numbering is according to human PINK1. Mutations were introduced into full-length TcPINK1 (1–570), and
enzymes (1 mg) were incubated in presence of PINKtide (1 mM) and [g-
32P] ATP for 30 min. Reactions were terminated by spotting onto P81 paper, washing in
phosphoric acid and quantifying phosphorylation of PINKtide bound to P81 paper. The results are presented as +s.d. for three experiments undertaken in duplicate.
Representative Coomassie-stained gels showing the relative amounts of PINK1 enzyme used for each assay are shown. (b) Inset: Schematic of the location of C-
terminally truncating PINK1 mutations. Numbering is according to human PINK1. Mutations were introduced into full-length TcPINK1 (1–570), enzymes( 1mg)
were incubated in presence of PINKtide (1 mM) and [g-
32P] ATP for 30 min. Reactions were terminated by spotting onto P81 paper, washing in phosphoric acid and
quantifying phosphorylation of PINKtide bound to P81 paper. The results are presented as +s.d. for two experiments undertaken in duplicate. Representative
Coomassie-stained gels showing the relative amounts of PINK1 enzyme used for each assay are shown.
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7mitochondrial-binding region, it could impact on recruitment
of PINK1 to the mitochondrial membrane. It could also affect
the interaction of PINK1 with an upstream activator or
physiological substrate.
Many kinase inhibitors are being developed for the treat-
ment of diseases involving aberrant protein phosphorylation.
As it has not previously been possible to assay PINK1 kinase
activity, it is not known whether the numerous kinase inhibi-
tors currently in preclinical development or clinical use may
also inhibit PINK1. It should also be noted that a recent
study has advocated that PINK1 inhibitors might have utility
in treating certain forms of colorectal cancer with mutations
in mismatch repair genes MSH2, MLH1 and MSH6 [20]. A
key issue with this is whether administration of PINK1 inhibi-
tors to human cancer patients could have the potential to
induce Parkinson’s disease. In the literature, the youngest
age of the onset of Parkinson’s disease in patients harbouring
homozygous PINK1 mutations is approximately 10 (A217D
mutation) [21], suggesting that at least a decade of PINK1
inhibition is required before Parkinson’s disease symptoms
develop. It is thus likely that short periods of exposure to
compounds that inhibit PINK1 for cancer treatments would
carry a reduced risk of Parkinson’s disease compared with
chronic long-term treatment. Furthermore, chemical inhi-
bition of kinases rarely achieves a null effect and more
often confers a hypomorphic effect on kinase activity.
Taking these factors into consideration, we feel that PINK1
inhibitors would be associated with a lower risk compared
with disease-causing Parkinson’s disease mutations that
inactivate PINK1 (figure 4a; electronic supplementary
material, figure S10). We also suggest that insect PINK1
could be introduced into kinase panels used to profile
kinase inhibitors being developed for the treatment of
human disease, at least until it is worked out how to activate
and assay human PINK1. Insect PINK1 could also be
deployed to attempt to identify PINK1 inhibitors for the treat-
ment of cancer, although further work would be needed to
ascertain whether an inhibitor of insect PINK1 would also
effectively suppress mammalian PINK1.
In conclusion, we report for the first time a novel method
to express an active form of PINK1. This has enabled us to
develop an assay to quantitatively assess PINK1 activity
and investigate its substrate specificity. Our work suggests
that, with the exception of the C125G mutation, all other
Parkinson’s disease mutations assessed are likely to exert
their disease-causing effects by suppressing kinase catalytic
activity. These observations emphasize the importance of
PINK1 kinase activity in preventing the onset of Parkinson’s
disease, and that the key challenge in future will be to ident-
ify PINK1 substrates and study the relevance of these in
Parkinson’s disease. We hope that the results presented in
this study will aid with assaying PINK1 catalytic activity
and in the hunt for substrates of this enzyme.
5. Material and methods
5.1. Reagents
Amylose resin was from New England Biolabs (Ipwich, MA).
[g-
32P] ATP was from PerkinElmer (Waltham, MA). P81
paper was from Whatman (Maidstone, UK). Bovine myelin
basic protein and bovine casein were from Sigma (St Louis,
MO), bovine histone H1 was from Abcam (Cambridge, UK).
PINKtide and its derivatives were synthesized by GL Biochem
(Shanghai, China). Restriction enzyme digests, DNA ligations
and other recombinant DNA procedures were performed
using standard protocols. All mutagenesis was carried out
using the QuikChange site-directed-mutagenesis method
(Stratagene, Santa Clara, CA) with KOD polymerase (Novagen,
Merck, Whitehouse Station, NJ). All DNA constructs were
verified by DNA sequencing, which was performed by The
Sequencing Service, School of Life Sciences, University
of Dundee, using DYEnamic ET terminator chemistry (Amer-
sham Biosciences, GE Healthcare, Little Chalfont, UK) on
Applied Biosystems (Foster City, CA) automated DNA sequen-
cers. cDNA for T. castaneum PINK1 and P. humanus corporis
PINK1 were synthesized by GenScript USA (Piscataway, NJ).
5.2. Buffers
Lysisbuffercontained50 mMTris–HCl(pH7.5),150 mMNaCl,
1 mMEDTA,1 mMethyleneglycoltetraaceticacid(EGTA),5per
cent (v/v)glycerol,1percent (v/v)TritonX-100,0.1percent (v/
v) 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM phenyl-
methylsulphonyl fluoride (PMSF). Wash buffer contained
50 mM Tris–HCl (pH 7.5), 500 mM NaCl, 0.1 mM EGTA,
5 per cent (v/v) glycerol, 0.03 per cent (v/v) Brij-35, 0.1 per
cent (v/v) 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM
PMSF. Equilibration buffer contained 50 mM Tris–HCl (pH
7.5), 150 mM NaCl, 0.1 mM EGTA, 5 per cent (v/v) glycerol,
0.03 per cent (v/v) Brij-35, 0.1 per cent (v/v) 2-mercaptoethanol,
1 mM benzamidine and 0.1 mM PMSF. Elution buffer was equi-
libration buffer with the addition of 12 mM maltose. Storage
buffer was equilibration buffer with the addition of 0.27 M
sucrose, and glycerol, PMSF and benzamidine were omitted.
5.3. Expression and purification of recombinant kinases
All PINK1 enzymes used in this study were expressed in E. coli
as maltose-binding protein fusion (MaBP) proteins. In addition,
human MaBP-PINK1 (125-end) was also expressed in Sf9 cells.
Briefly, BL21 Codonþ transformants were grown at 378Ct oa n
OD600 of 0.3, shifted to 168C and induced with 250 mMI P T G
(isopropyl b-D-thiogalactoside) at OD600 ¼ 0.5. Cultures were
then grown for a further 15–16 h at 168C. Cells were lysed by
sonication in lysis buffer. Lysates were clarified by centrifugation
at 30 000gfor30 minat48C followedbyincubationwith 1 mlper
litre of culture of amylose resin for 1.5 h at 48C. The resin was
washed thoroughly in wash buffer, then equilibration buffer,
and proteins were then eluted. Proteins were dialysed overnight
at 48C into storage buffer, snap frozen and stored at 2808Cu n t i l
use. Expression of human PINK1 in Sf9 cells was conducted as
follows. Sf9 cells were seeded at a density of 1.5   10
6cells ml
21
and 1:10 P2 virus was added. Cells were incubated in spinner
flasks in the dark at 278C for 4 days, after which point the cells
were harvested and the protein was purified using the MaBP
affinity tag as above. Bacmids were produced and viruses
amplified according to standard protocols.
5.4. Kinase assays
Assays using protein substrates were set up in a volume of
40 ml, with substrates at 2 mM and all kinases at 1 mgi n
50 mM Tris–HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2,
2 mM dithiothreitol and 0.1 mM [g-
32P] ATP. Assays were
r
s
o
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
O
p
e
n
B
i
o
l
1
:
1
1
0
0
1
2
8incubated at 308C with shaking at 1200 r.p.m. and terminated
after 30 min by addition of sodium dodecyl sulphate (SDS)
sample buffer. Reaction mixtures were resolved by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were detected by Coomassie staining.
Incorporation of [g
232P] ATP into substrates was analysed
by autoradiography.
Forassays using peptide substrates, assays were set up in a
volume of 50 ml, with all kinases at 1 mM and peptide sub-
strates at the indicated concentrations in 50 mM Tris–HCl
(pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM dithiothreitol
and 0.1 mM [g-
32P] ATP. Assays were incubated for 30 min
at 308Cwith shaking at 1200 r.p.m.,and terminated byspotting
of 40 ml of the reaction mixture onto P81 phosphocellulose
paper and washing in 50 mM phosphoric acid. After extensive
further washing, incorporation of [g-
32P] ATP into substrates
was quantified by Cerenkov counting. For MBP assays using
P81 paper, 5 mg of MBP was used.
One unit of TcPINK1 activity was defined as the amount
of enzyme that catalysed the incorporation of 1 nmol of ATP
into a given substrate. Km and Vmax values were determined
by analysing the phosphorylation of PINKtide and its var-
iants at various concentrations. Km and Vmax values were
calculated using the GRAPHPAD PRISM program.
5.5. Multiple sequence alignment
PINK1 sequences were aligned with MUSCLE (MUltiple
Sequence Comparison by Log-Expectation), EBI (www.ebi.
ac.uk/Tools/muscle/index.html) and managed with JalView
(www.jalview.org/).
5.6. Analysis of Drosophila phenotypic rescue
Drosophila were raised under standard conditions at 258Co n
agar, cornmeal and yeast food. PINK1
B9 mutants, da-GAL4
line and assays for flight, climbing and thoracic indentations
have been described previously [22]. Full-length coding
sequence for Tribolium or Pediculus PINK1 was cloned into
the pUAST transgenesis vector and transgenic lines were gen-
erated by standard techniques in a w
1118 background
(BestGene Inc., Chino Hills, CA). Multiple independent
lines were assessed for consistency.
5.7. Mass spectrometry
Samples were analysed by an Applied Biosystems 4000
Q-TRAP system with precursor ion scanning as described
previously [23].
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